Nanog Requires BRD4 to Maintain Murine Embryonic Stem Cell Pluripotency and Is Suppressed by Bromodomain Inhibitor JQ1 Together with Lefty1

Stem Cells and Development

Volumn 24, Issue 7, 2015, Pages 879-891

  Horne, Gillian A ^a   Stewart, Helen J S ^a   Dickson, Jacqueline ^b   Knapp, Stefan ^c   Ramsahoye, Bernard ^b   Chevassut, Timothy ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BRD4 PROTEIN; BUTYRIC ACID; HISTONE ACETYLTRANSFERASE; LEFT RIGHT DETERMINATION FACTOR; LEFTY1 PROTEIN; LEFTY2 PROTEIN; MYC PROTEIN; PROTEIN; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; VALPROIC ACID; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; LEFTY1 PROTEIN, MOUSE; NANOG PROTEIN, MOUSE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HISTONE ACETYLATION; IMMUNOCYTOCHEMISTRY; LEUKEMIA; MICROARRAY ANALYSIS; MOUSE; MYELOMA CELL; NONHUMAN; ONCOGENE C MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REGULATORY MECHANISM; STEM CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM;

MURINAE;

ANIMALS; AZEPINES; CELLS, CULTURED; EMBRYONIC STEM CELLS; HOMEODOMAIN PROTEINS; LEFT-RIGHT DETERMINATION FACTORS; MICE; NANOG HOMEOBOX PROTEIN; NUCLEAR PROTEINS; PLURIPOTENT STEM CELLS; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84925237186     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0302     Document Type: Article

References (40)

1. Evans MJ and MH Kaufman. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-156.
2. Chambers I and A Smith. (2004). Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene 23:7150-7160.
3. Yamanaka SaKO. (2006). Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Curr Stem Cell Res Ther 1:103-111.
4. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
5. Li X, CAS Corsa, PW Pan, L Wu, D Ferguson, X Yu, J Min and Y Dou. (2010). MOF and H4 K16 Acetylation play important roles in DNA damage repair by modulating recruitment of DNA damage repair protein Mdc1. Mol Cell Biol 30:5335-5347.
6. Li X, L Li, R Pandey, JS Byun, K Gardner, Z Qin and Y Dou. (2012). The histone acetyltransferase MOF is a key regulator of the embryonic stem cell core transcriptional network. Cell Stem Cell 11:163-178.
7. Zeng L and MM Zhou. (2002). Bromodomain: an acetyllysine binding domain. FEBS Lett 513:124-128.
8. Filippakopoulos PKS. (2012). The bromodomain interaction module. FEBS Lett 586:2692-2704.
9. Dawson MA, T Kouzarides and BJP Huntly. (2012). Targeting epigenetic readers in cancer. N Engl J Med 367:647-657.
10. Filippakopoulos P, S Picaud, M Mangos, T Keates, J-P Lambert, D Barsyte-Lovejoy, I Felletar, R Volkmer, S Müller, et al. (2012). Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149:214-231.
11. Filippakopoulos P, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, EM Morse, T Keates, TT Hickman, et al. (2010). Selective inhibition of BET bromodomains. Nature 468:1067-1073.
12. Zuber J, J Shi, E Wang, AR Rappaport, H Herrmann, EA Sison, D Magoon, J Qi, K Blatt, et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478:524-528.
13. Delmore Jake E, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, T Gilpatrick, RM Paranal, et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904-917.
14. Mertz JA, AR Conery, BM Bryant, P Sandy, S Balasubramanian, DA Mele, L Bergeron and RJ Sims. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108:16669-16674.
15. Dawson MA, RK Prinjha, A Dittmann, G Giotopoulos, M Bantscheff, W-I Chan, SC Robson, C-w Chung, C Hopf, et al. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478:529-533.
16. Picaud S, D Da Costa, A Thanasopoulou, P Filippakopoulos, PV Fish, M Philpott, O Fedorov, P Brennan, ME Bunnage, et al. (2013). PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 73:3336-3346.
17. Matzuk Martin M, MR McKeown, P Filippakopoulos, Q Li, L Ma, Julio E Agno, Madeleine E Lemieux, S Picaud, Richard N Yu, et al. (2012). Small-molecule inhibition of BRDT for male contraception. Cell 150:673-684.
18. Hooper M, K Hardy, A Handyside, S Hunter and M Monk. (1987). HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326:292-295.
19. O'Neill LP, MD VerMilyea and BM Turner. (2006). Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 38:835-841.
20. Ververis K, AL Rodd, MM Tang, A El-Osta and TC Karagiannis. (2011). Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci 68:4101-4114.
21. McCool KW, X Xu, DB Singer, FE Murdoch and MK Fritsch. (2006). The role of histone acetylation in regulating early gene expression patterns during early embryonic stem cell differentiation. J Biol Chem 282:6696-6706.
22. Sawan C, H Hernandez-Vargas, R Murr, F Lopez, T Vaissière, AY Ghantous, C Cuenin, J Imbert, Z-Q Wang, B Ren and Z Herceg. (2013). HAT cofactor trrap maintains self-renewal and restricts differentiation of embryonic stem cells. Stem Cells 31:979-991.
23. Saraiva NZ. (2010). Histone acetylation and its role in embryonic stem cell differentiation. World J Stem Cells 2:121.
24. Lamonica JM, W Deng, S Kadauke, AE Campbell, R Gamsjaeger, H Wang, Y Cheng, AN Billin, RC Hardison, JP Mackay and GA Blobel. (2011). Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci USA 108:159-168.
25. Wu SY, AY Lee, HT Lai, H Zhang and CM Chiang. (2013). Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49:843-857.
26. Drost J, F Mantovani, F Tocco, R Elkon, A Comel, H Holstege, R Kerkhoven, J Jonkers, PM Voorhoeve, R Agami and G Del Sal. (2010). BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 12:380-389.
27. Herrmann H, K Blatt, J Shi, AR Rappaport, KV Gleixner, S Cerny-Reiterer, B Peter, E Wang, WR Sperr, et al. (2011). Small-molecule inhibition of BRD4 is a novel promising approach to therapeutically target leukemia stem cells in AML. ASH Annual Meeting Abstracts 118:3484.
28. Lockwood WW, K Zejnullahu, JE Bradner and H Varmus. (2012). Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109:19408-19413.
29. Schwartz BE, MD Hofer, ME Lemieux, DE Bauer, MJ Cameron, NH West, ES Agoston, N Reynoird, S Khochbin, et al. (2011). Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 71:2686-2696.
30. Ware CB, L Wang, BH Mecham, L Shen, AM Nelson, M Bar, DA Lamba, DS Dauphin, B Buckingham, et al. (2009). Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell 4:359-369.
31. http://p53.free.fr/Database/Cancer-cell-lines/p53-cell-lines.html
32. Fazzio TG, JT Huff and B Panning. (2008). An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity. Cell 134:162-174.
33. Zhong X and Y Jin. (2009). Critical roles of coactivator p300 in mouse embryonic stem cell differentiation and Nanog expression. J Biol Chem 284:9168-9175.
34. Loizou JI, G Oser, V Shukla, C Sawan, R Murr, ZQ Wang, A Trumpp and Z Herceg. (2009). Histone acetyltransferase cofactor Trrap is essential for maintaining the hematopoietic stem/progenitor cell pool. J Immunol 183:6422-6431.
35. Kretsovali A, C Hadjimichael and N Charmpilas. (2012). Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int 2012:1-10.
36. Meno C, Y Saijoh, H Fujii, M Ikeda, T Yokoyama, M Yokoyama, Y Toyoda and H Hamada. (1996). Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature 381:151-155.
37. Kim DK, Y Cha, HJ Ahn, GI Kim and KS Park. (2013). Lefty1 and Lefty2 control the balance between self-renewal and pluripotent differentiation of mouse embryonic stem cells. Stem Cells Dev 23:457-466.
38. Dreesen O and AH Brivanlou. (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3:7-17.
39. Wong RCB, MF Pera and A Pé bay. (2008). Role of gap junctions in embryonic and somatic stem cells. Stem Cell Rev 4:283-292.
40. Ben-Porath I, MW Thomson, VJ Carey, R Ge, GW Bell, A Regev and RA Weinberg. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499-507.